Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)
Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on our FORUM positive ASPS response to the drug. The conclusion that Cediranib shows favorable activity in ASPS is detailed in a summary of a Phase 2 clinical trial by Dr. Kummar in the 2011 meeting of the American Society of […]
Update on the Cediranib and Sunitinib Clinical Trials for Alveolar Soft Part Sarcoma Phase II in the USA
Please note the two Phase II clinical trials available for ASPS patients in the US: 1. Sunitinib or Cediranib for Alveolar Soft Part Sarcoma, study number NCT01391962 Contact: NCI Referral Office, Tel. 1-888-NCI-1937 Locations: United States, California Santa Monica Oncology Center Santa Monica, California, United States, 90403 United States, Maryland National Institutes of Health […]
New Clinical Trial for Alveolar Soft Part Sarcoma in the United Kingdom: CASPS – A Phase II Trial of Cediranib
Dear ASPS Community, We are very happy to report the opening of another clinical trial for ASPS patients in the United Kingdom. This new clinical trial is a phase II trial of Cediranib. Every trial brings with it the hope for cure! ASPS patients who are trying Cediranib are sharing their experience on iCureASPS Forum. […]
Tumor Expression Profile of Alveolar Soft Part Sarcoma May Pave the Way for New Treatments at The Dana Farber Cancer Institute
Scientists from the group of Dr. Massimo Loda reported the results of an extensive study that aims to identify potential therapeutic targets for ASPS last Friday. The research team, comprised of Shamini Selvarajah (PhD), Eleanor Chen (MD, PhD), and Saumyadipta Pyne (PhD), used cDNA microarray technology (gene expression array) to examine the expression of 18,401 […]
Cediranib (AZD2171): Phase II Study in Patients With Alveolar Soft Part Sarcoma
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug inhibits angiogenesis: the formation of new blood vessels. Angiogenesis, in the context of cancer, enables blood supply to tumors, resulting in tumor growth and spread. Cediranib is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral […]
Feedback II – The GVAX Cancer Vaccine Trial at the Dana Farber
The GVAX cancer vaccine clinical trial, which has been opened in January 2006 is no more recruiting new patients. When it was open it recruited in addition to Alveolar Soft Part Sarcoma also Clear Cell Sarcoma, Renal Cell Carcinoma and Melanoma patients. In June 2007 I shared with you an e-mail from a parent whose […]
A Press Release – ARQ197
ArQule Achieves Clinical Milestone in MiT Trial with ARQ 197 Thursday October 2, 8:01 am ET Confirmed tumor response in clear cell sarcoma leads to expanded trial WOBURN, Mass.–(BUSINESS WIRE)–ArQule, Inc. (NASDAQ: ARQL – News) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of […]
Update: ARQ 197 – New Clinical Trial for Patients with Alveolar Soft Part Sarcoma
Previously, we reported that Alveolar Soft Part Sarcoma is a candidate for therapy by drugs that inhibit the MET receptor tyrosine kinase. Then, we reported the opening of a clinical trial of such an inhibitor, ARQ 197, in California. This clinical trial is now open in many more locations in the USA, and may soon be available in […]
ARQ 197: New Clinical Trial for Patients with Alveolar Soft Part Sarcoma
Update on the ARQ 197 Clinical Trial (November 23): The new clinical trial (read below) is now open and at least two ASPS patients are already participating in it. If you are interested to join the trial please read the information below and contact Dr. Isett Laux, the study coordinator for this study. Tel: 310-633 […]
Feedback – The GVAX Cancer Vaccine Trial at the Dana Farber
Dear ASPS community. As you probably know, the GVAX cancer vaccine clinical trial has been open since January 2006 and is still recruiting new patients. In addition to Alveolar Soft Part Sarcoma, it also recruits Clear Cell Sarcoma, Renal Cell Carcinoma and Melanoma patients. I would like to share with you an e-mail from a […]